Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVX9I0)

Drug Name

Des-Arg(9)-[Leu(8)]-BK Drug Info

Synonyms

5-Chloro-4-(N-(cyclopropyl)methyl-N-propylamino)-2-methyl-6-(2,4,6-trichlorophenyl)aminopyridine; NBI 27914; NBI27914; NBI-27914; CHEMBL45281; SR-01000075865; Tocris-1591; Lopac-N-3911; AC1L41YH; Lopac0_000493; MLS000860080; cid_176157; GTPL3512; SCHEMBL16606734; CHEBI:93069; DTXSID20171549; HMS3261D07; HMS3371C20; HMS2230I15; ZINC2511843; Tox21_500493; BDBM50054245; CCG-204584; API0008466; LP00493; 2-methyl-4-(N-propyl-N-cycloproanemethylamino)-5-chloro-6-(2,4,6-trichloranilino)pyrimidine; NCGC00261178-01; NCGC00015737-05

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Investigative	[1]

Cross-matching ID

PubChem CID: 176157
ChEBI ID: CHEBI:93069
CAS Number: CAS 184241-44-9
TTD Drug ID: DMVX9I0

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Corticotropin-releasing factor receptor 1 (CRHR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Telavancin	DM58VQX	Staphylococcus infection	1B5Y	Approved	[3]
Pexacerfont	DMBJ15R	Anxiety disorder	6B00-6B0Z	Phase 2/3	[4]
SSR125543	DMGJEB8	Anxiety disorder	6B00-6B0Z	Phase 2	[5]
ONO-2333Ms	DMOT0WR	Anxiety disorder	6B00-6B0Z	Phase 2	[6]
GSK561679	DMEVARK	Alcohol dependence	6C40.2	Phase 2	[7]
Tildacerfont	DMAB8LH	Congenital adrenal hyperplasia	5A71.01	Phase 2	[8]
GSK586529	DM5E9LX	Anxiety disorder	6B00-6B0Z	Phase 1	[7]
GW876008	DMAXRBI	Irritable bowel syndrome	DD91.0	Discontinued in Phase 2	[4]
CP-316,311	DMZ76EM	Major depressive disorder	6A70.3	Discontinued in Phase 2	[4]
CRA1000	DMWMBIV	Anxiety disorder	6B00-6B0Z	Preclinical	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting B1 bradykinin receptor (BDKRB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SSR-240612	DMFNZPY	Rheumatoid arthritis	FA20	Phase 2	[9]
Safotibant	DMKDP57	Diabetic macular edema	9B71.02	Phase 2	[10]
BI 113823	DMUJ1EL	Osteoarthritis	FA00-FA05	Phase 1	[11]
H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638)	DM6839G	Discovery agent	N.A.	Investigative	[12]
H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669)	DMTGU0L	Discovery agent	N.A.	Investigative	[12]
H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645)	DMDXIS7	Discovery agent	N.A.	Investigative	[12]
JMV1431	DMAR3M2	Discovery agent	N.A.	Investigative	[12]
Ac-Lys-[Leu(8)]-des-Arg(9)-BK	DMIAYTP	Discovery agent	N.A.	Investigative	[13]
NVP-SAA164	DMN90R6	Pain	MG30-MG3Z	Investigative	[14]
Des-Arg10-Kallidin	DMZ5Y94	Discovery agent	N.A.	Investigative	[15]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B1 bradykinin receptor (BDKRB1)	TTG5QIA	BKRB1_HUMAN	Antagonist	[2]
Corticotropin-releasing factor receptor 1 (CRHR1)	TT7EFHR	CRFR1_HUMAN	Antagonist	[3]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3512).
2	Evidence for the participation of kinins in Freund's adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice. Neuropharmacology. 2001 Dec;41(8):1006-12.
3	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
4	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
5	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6	Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86.
7	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
8	Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021 Nov 30;186(1):R1-R14.
9	The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. Br J Pharmacol. 2007 September; 152(2): 280-287.
10	The role of kinin receptors in cancer and therapeutic opportunities. Cancer Letters Volume 345, Issue 1, 1 April 2014, Pages 27-38.
11	The bradykinin B1 receptor antagonist BI113823 reverses inflammatory hyperalgesia by desensitization of peripheral and spinal neurons. Eur J Pain. 2015 Jan;19(1):132-42.
12	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
13	Non-competitive pharmacological antagonism at the rabbit B(1) receptor. Br J Pharmacol. 2000 Nov;131(5):885-92.
14	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 659).
15	Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6045-8.